P-01 | Defining Cell Type-Specific Pathologies of Charcot-Marie-Tooth Type 4B3 in a Novel iPSC-based Model System
Xinyi Mao, Malika Sharma, Jason Chua
P-03 | Innovated Solutions Evolving from Community Based Leadership and PD Community Voice Input To Increase Diverse Enrollment in Clinical Trial Research
R. Bernard Coley, Denise Coley
P-04 | Evaluation and Treatment of Parkinson’s and Lewy Body Disease Psychosis in Medstar Georgetown University Hospital Comprehensive Cognition Clinic
Thaddeus McGinn, Gonul Ozay, Yasar Torres-Yaghi, Fernando Pagan
P-05 | Determining Cognitive Impairment Through a Comprehensive Cognition Clinic in Patients with Parkinson’s and Lewy Body Disease
Willa Riekhof, Gonul Ozay, Fernando Pagan, Yasar Torres-Yaghi
P-06 | Istradefylline effects on L-Dopa resistant tremor in Parkinson’s disease
Gonul Ozay, Irma Zhang, Michelle Umali, Luke Lovelace, Michael Barry, Lina Ariza Serrano, Alexandre Mason-Sharma, Lana Raslan, Yasar Torres-Yaghi, Fernando L. Pagan
P-07 | Participation in a Mindfulness Program to Improve Non-Motor Symptoms for Individuals with Parkinson’s Disease
Randi Loomis, Nancy Harris
P-08 | Duration of Illness and Response to Pimavanserin in Parkinson’s Disease Psychosis: Post-Hoc Analysis of Clinical Trial Data
Khashayar Dashtipour, Alberto Espay, Michele Tagliati, Gregory Brunson, Xiaoshu Feng, Nazia Rashid, Lambros Chrones
P-09 | Understanding Providers’ Utilization and Perceptions of Subcutaneous Infusion Therapies for Patients With Advanced PD
Taylor Clark, Melissa Long, Elizabeth Rappa, SuEllen Farrell, Jani Hagerty, Daniel Kremens
P-10 | Valbenazine Improves the Impacts and Symptoms of Tardive Dyskinesia: Topline Results from the Phase 4 KINECT-PRO™ Study
Eduardo Dunayevich, M. Mercedes Perez-Rodriguez, Joseph McEvoy, Ashok Parameswaran, Morgan Bron, Ericha Franey, Katherine Joseph, Donna Sparta, Cathy Zeng, Susan Mathias, Gustavo Alva, Christoph Correll
P-11 | Valbenazine Decreases Disease Burden Among Adults Treated for Huntington’s Disease Chorea: Post-Hoc Analyses of Motor-Related HD-HI Items From the KINECT®-HD Trial
Erin Furr Stimming, Hui Zhang, Olga Klepitskaya, Katherine Joseph, Dietrich Haubenberger, Sean Hinton, Chad Heatwole
P-12 | Valbenazine Decreases Disease Burden Among Adults Treated for Huntington’s Disease Chorea: Post-Hoc Analysis of Cognitive-Related HD-HI Items From the KINECT®-HD Trial
Erin Furr Stimming, Hui Zhang, Olga Klepitskaya, Brittany Harbert, Dietrich Haubenberger, Sean Hinton, Chad Heatwole
P-13 | Effect Sizes of Once-Daily Valbenazine for Tardive Dyskinesia and Chorea Associated with Huntington’s Disease: A Post-Hoc Analysis of Phase 3 Data
Robert Hauser, Raja Mehanna, Erin Furr Stimming, Leslie Citrome, Olga S. Klepitskaya, Brittany Harbert, Sean C. Hinton, Hui Zhang, Sara Gao, Eduardo Dunayevich, Grace Liang, Dietrich Haubenberger
P-14 | Sustained Chorea Improvements With Long-Term, Once-Daily Valbenazine in Adults With Huntington’s Disease
Erin Furr Stimming, Daniel O. Claassen, Elise Kayson, Raja Mehanna, Shree Karpuram, Heintje Calara, Jody Goldstein, Sean C. Hinton, Olga Klepitskaya, Hui Zhang, Sara Gao, Grace Liang, Dietrich Haubenberger
P-15 | Protocol and Demographics of the RELY-CD Study: Assessing Long-Term Clinical Response to Botulinum Neurotoxin in Cervical Dystonia
Benjamin Waeschle, John-Ih Lee, Marta Banach, Sara Sánchez Valiente, Georg Comes, Holger Stark, Philipp Albrecht
Presenter: Jennifer LoBraico
P-16 | Primary Results of the Initial Validation of the SMD Decision Tree – I-REFER
Klemens Fheodoroff, Benjamin Waeschle, Manuela Schuetzer, Georg Comes, Joerg Wissel
Presenter: Jennifer LoBraico
P-17 | Characteristics of incobotulinumtoxinA treatment for limb spasticity in a real-world setting: dosing and muscles injected
Michael Hast, Kofi Binney, Amanda M. Kong, Gulce Askin, Daniel Nomah, Daisha Joseph, Jordan Holmes
P-18 | Characteristics of incobotulinumtoxinA treatment for cervical dystonia in a real-world setting: dosing and muscles injected
Michael Hast, Jordan Holmes, Amanda M. Kong, Gulce Askin, Daniel Nomah, Daisha Joseph, Kofi Binney
P-19 | Brexpiprazole for agitation associated with dementia due to Alzheimer’s disease: number needed to treat, number needed to harm, and likelihood to be helped or harmed
Leslie Citrome, Sanjeda R. Chumki, Pedro Such, David Wang, Anton M. Palma, Zhen Zhang, Alireza Atri
Presenter: Kara Trotter
P-20 | Outcomes following initiation of amantadine DR/ER (Gocovri) in patients with Parkinson disease – evaluation of the American Academy of Neurology Axon Registry database
Mindy Grall, Nikkilina Crouse, Andrea Formella, Erin Zwick, Heather Moss
P-21 | Continuous Subcutaneous Apomorphine Infusion (CSAI) Improved Confidence When Engaging in Everyday Activities: Survey of InfusON Study Participants
Pinky Agarwal, Andrea Formella, Nikkilina Crouse, Arianne Breiteneicher, Mindy Grall
P-22 | Improvement in Uninterrupted Good ON Time and Reduction in OFF Periods with CSAI Treatment
Daniel Kremens, Robert Hauser, Andrea Formella, Milan Joshi, Mindy Grall
P-23 | Providing education and support programs for continuous subcutaneous apomorphine infusion (CSAI) in the United States
Nikkilina Crouse, Cindy Happel, Mindy Grall
P-24 | Patient Experiences Initiating Continuous Subcutaneous Apomorphine Infusion (CSAI): An Interview-Based Survey of InfusON Study Participants
Pinky Agarwal, Nikkilina Crouse, Arianne Breiteneicher, Mindy Grall
P-25 | Functional activity of apomorphine relative to dopamine at dopamine receptors: Findings from G protein coupled receptor biosensor assays
Brittney Yegla, Mindy Grall, Jonathan Rubin
P-26 | Preliminary Efficacy of GDNF Gene Therapy (AAV2-GDNF; AB-1005) in Parkinson’s Disease: 36-Month Follow-Up From a Phase 1b Study
Nicolas Phielipp, Chadwick Christine, Aristide Merola, J. Bradley Elder, Paul Larson, Waldy San Sebastian, Massimo Fiandaca, Christian Urrea, Michael Wisniewski, Amber Van Laar, Adrian Kells, Krystof Bankiewicz
Presenter: Nisha Chhabria
P-27 | Changes in Motor States Throughout the Waking Day With Tavapadon in People With Parkinson’s Disease
Robert Hauser, Rajesh Pahwa, Linda Harmer, Amber Lind
P-28 | Tavapadon Is Not Associated With Increased Daytime Sleepiness in People With Parkinson’s Disease
Rajesh Pahwa, Zoltan Mari, William Ondo, Linda Harmer, Amber Lind, Robert Hauser
P-29 | Efficacy and Safety of Tavapadon, an Orally Administered, Once-Daily, Selective D1/D5 Dopamine Agonist, Adjunctive to Levodopa for Treatment of Parkinson’s Disease With Motor Fluctuations
Hubert Fernandez, Stuart Isaacson, Robert Hauser, Pinky Agarwal, William Ondo, Ariane Park, Lawrence Elmer, Daniel Kremens, Matthew Leoni, Sridhar Duvvuri, Cari Combs, Erica Koenig, Ih Chang, Gina Pastino, Stacey Tringali, Nicole Golonski, Raymond Sanchez
Presenter: Linda Harmer
P-30 | Efficacy and Safety of Flexible-Dose Tavapadon, an Orally Administered, Once-Daily, Selective D1/D5 Dopamine Agonist for the Treatment of Early Parkinson’s Disease
Hubert Fernandez, Perminder Bhatia, Leslie Cloud, Urban Fietzek, Michele Matazarro, Eric Molho, Elizabeth Peckham, Arjun Tarakad, Cari Combs, Matthew Leoni, Ih Chang, Stacey Tringali, Joey Boiser, Cindy Zadikoff, Raymond Sanchez
Presenter: Linda Harmer
P-31 | Efficacy and Safety of Fixed-Dose Tavapadon, an Oral, Once-Daily, Selective D1/D5 Dopamine Agonist for the Treatment of early Parkinson’s disease
Rajesh Pahwa, Elena Moro, Alberto J. Espay, Andrew Evans, Angelo Antonini, Marie Saint-Hilaire, Diego Torres-Russotto, Raymond Sanchez, Matthew Leoni, Sridhar Duvvuri, Cari Combs, Ih Chang, Stacey Tringali
P-32 | Long-term Efficacy of 24-Hour Subcutaneous Levodopa/Carbidopa Infusion (Investigational ND0612) for Motor Fluctuations in Parkinson’s Disease
Alberto Espay, Rajesh Pahwa, Aaron L. Ellenbogen, Fabrizio Stocchi, Laurence Salin, Nissim Sasson, Jonathan Pereira, Olivier Rascol
P-33 | Improvement in Morning Akinesia After Foslevodopa/Foscarbidopa Treatment was Associated with Significantly Improved Motor Fluctuations, Activities of Daily Living, and Quality of Life in People with Parkinson’s Disease
Rajesh Pahwa, Sara Dhanani, Eleni Okeanis Vaou, Diego Santos Garcia, Bruno Bergmans, Lars Bergmann, Linda Harmer, Resmi Gupta, Megha Shah, Thomas Kimber, Angelo Antonini
Presenter: Michelle Oliveira Fernandes
P-34 | Evaluation of Infusion Site Adverse Events With Foslevodopa/Foscarbidopa in a 12 Week, Randomized Study
Stuart Isaacson, Robert Kirsner, Okeanis Vaou, Rajesh Pahwa, Robert Hauser, Lars Bergmann, Resmi Gupta, Megha Shah, Shane Varughese, Thomas Kimber
Presenter: Pavnit Kukreja
P-35 | Correlation Between Sleep and Quality of Life in People With Parkinson’s Disease Treated With Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa
Irene Malaty, Eleni Okeanis Vaou, Robert Hauser, Bruno Bergmans, Per Odin, Megha Shah, Lars Bergmann, Linda Harmer, Resmi Gupta, K. Ray Chaudhuri
Presenter: Pavnit Kukreja
P-36 | Initiation of Pimavanserin among Newly Diagnosed Patients with Parkinson’s Disease Psychosis: A 6-month Pre-Post Analysis of Health Care Resource Utilization Differences Among Medicare Beneficiaries
Nazia Rashid, Krithika Rajagopalan, Daksha Gopal, Lambros Chrones, Dilesh Doshi
P-37 | MR-Guided Focused Ultrasound for Essential Tremor and Parkinson’s Disease: Landscape of Approved Patient Therapies and Ongoing Trials
Regina Martuscello, Lindsay Knight, Ángeles Sánchez Fraga, Ian Pyle, Cyril Ferrer, Katie Gant, Augusto Grinspan
P-38 | Understanding the Challenges of Treating and Living with Essential Tremor: Results from a Lived-Experience Focus Group
Regina Martuscello, Lindsay Knight, Ángeles Sánchez Fraga, Ian Pyle, Cyril Ferrer, Katie Gant, Augusto Grinspan
P-39 | Clinical Profile of AXS-05 in Treating Alzheimer’s Disease-Related Agitation: Results From the ADVANCE-1 and ACCORD-1 Randomized, Placebo-Controlled Studies
Jeffery Cummings, George Grossberg, Caroline Streicher, Michael Tocco
P-40 | Modified titration of donanemab reduced ARIA-E risk and maintained amyloid reduction: 12-month results from TRAILBLAZER-ALZ 6
Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, Rashna Khanna, Diana Otero Svaldi, Sergey Shcherbinin, Scott Andersen, Paula Hauck, Staci Engle, Dawn Brooks, Emily C. Collins, Mark Mintun, John Sims, Adewale Adeluyi
P-41 | Quality of life with 24-hour subcutaneous levodopa/carbidopa infusion (investigational ND0612): PDQ-39 results from a Phase 3 randomized, active-controlled study
Harini Sarva, Michele Tagliati, Werner Poewe, Fabrizio Stocchi, Olivier Rascol, Tami Yardeni, Nelson Lopes, Jonathan Pereira, Alberto Espay
Presenter: Amanda Goldberg
P-42 | Dopaminergic Adverse Events With 24-Hour Subcutaneous Infusion of Investigational ND0612
Stuart Isaacson, Olivier Rascol, Harini Sarva, Robert Hauser, Fabrizio Stocchi, Nelson Lopes, Laurence Salin, Jonathan Pereira
Presenter: Huyen Phan
P-43 | Advanced Deep Brain Stimulation (DBS) Programming Using Combined Interleaving and Cycling Programming (ICP)
Pamela Rose Zeilman, Patricia Graese, Rachael Burke, Joshua Wong
P-44 | Advanced Deep Brain Stimulation (DBS) Programming using Interleaving
Pamela Rose Zeilman, Patricia Graese, Rachael Burke, Joshua Wong
P-45 | Advanced deep brain stimulation (DBS) programming utilizing duty-cycle settings
Patricia Graese, Rachael Burke, Joshua Wong, Pamela Rose Zeilman
P-46 | Improving the Quality and Safety of Care for Hospitalized Patients with Parkinson’s Disease
Patricia Clark, Tatiana Lopez Gonzalez, Laurie Moser, Camila Piccinin, Shannon Shaffer, Benjamin Walter, Brent Sokola, Kim Lewin, Anne Brooks
P-47 | Estimation of the Minimal Clinically Important Difference (MCID) and Longitudinal Change in the Tardive Dyskinesia Impact Scale (TDIS), a Validated, Tardive Dyskinesia-Specific, Patient-Reported Outcome Measure
Morgan Bron, Susan Mathias, Sara Gao, Connie Ly, Dawn Vanderhoef, Hui Zhang, Eduardo Dunayevich, M. Mercedes Perez-Rodriguez, Christoph Correll
Presenter: Heintje Calara
P-48 | Comparative Safety of Istradefylline in Parkinson’s Disease: A Systematic Review of Randomized Controlled Trials and Real-World Studies
Sagari Betté, Joyce Qian, Hannah Cummings, Katsumi Shinoda, Hiroo Shimoda, Ashley Thai, Sarah Batson, Stephen Mitchell, Alexander Hodkinson, Daniel Truong
P-49 | SUNRISE-PD: An Ongoing, Hybrid, Decentralized Phase 2 Study of Bezisterim (NE3107) in Early Parkinson’s Disease
Mark Stacy, Joseph Palumbo, Clarence Ahlem, Christopher Reading, Jeffrey Zhang
P-50 | Comparative analysis of opicapone and entacapone in the management of motor fluctuations in patients with Parkinson’s disease, from clinical trials to healthcare resource usage
Daniel Kremens, Fahd Amjad, Sandeep Thakkar, Bita Naderi, Diogo Martins, José-Francisco Rocha, Ghazal Banisadr, Stanley Fisher
P-51 | Conversion to CREXONT® in the RISE-PD phase 3 trial improved aspects of sleep as measured by the Parkinson’s disease sleep scale-2 (PDSS-2)
William Ondo, Robert Hauser, Zachary Grieb, Ghazal Banisadr, Stanley Fisher
P-52 | Impact of CREXONT on Parkinson’s patients’ motor states upon awakening: analysis of patient diary data
Stuart Isaacson, Hubert Fernandez, Camilla Kilbane, Ghazal Banisadr, Arkadiy Pitman, Stanley Fisher, Richard D’Souza
P-53 | Gender differences in the effect of deep brain stimulation on depression, anxiety and quality of life in Parkinson’s Disease
Molly Abbott, Arteen Ahmed, David Okai, Michael Samuel, Keyoumars Ashkan, Edward Newman, Antonella Macerollo, Jibril Osman Farah, Monty Silverdale, Nagaraja Sarangmat, Anjum Misbahuddin, David Ledingham, Nicola Pavese, Michelle Gibbs, Russel Mills, Paul Shotbolt
P-54 | Acupuncture Effect on Reaction Time Changes in Parkinson Disease Patients – A Protocol Study
Xinyi Mao, Malika Sharma, Jason Chua
Presenter: Catarina Pereira
P-55 | Burden of tremor in Parkinson’s disease: A survey study
Robert Hauser, Tara Crowder Skarpaas, Andréa Merriam, Jason Rivera, Valmira Hoxhaj, Luigi M. Barbato, Anita Chadha-Patel, Michelle Baladi
P-56 | Significant Improvements in Motor and Non-Motor symptoms with Corresponding Neuroimaging Changes Following Hybrid Levodopa – Digital Application Treatment in Parkinson’s Patients
Amir Amedi, Nira Saporta, Liza Veinger, Sheila Oren, Rotem Sivan Hoffmann, Tal Tamir, Shai Erlich, Dina Kofler, Shira Molcho, Gal Gorelik, Merav Catalogna
Presenter: Brett Colbert
P-57 | Hybrid Treatment with the DopApp Digital Application Significantly Improved UPDRS in Levodopa-Treated Parkinson’s Patients in a Double-Blind, Placebo-Controlled Trial
Nira Saporta, Liza Veinger, Sheila Oren, Merav Catalogna, Rotem Sivan Hoffmann, Tal Tamir, Shai Erlich, Dina Kofler, Shira Molcho, Gal Gorelik, Amir Amedi
Presenter: Brett Colbert
P-58 | The Syn-One Test®: A Patient Perspectives Study
Padma Mahant, Rushil Pithia, Todd Levine, Christopher Gibbons, Karl Kieburtz, Roy Freeman
